IFN-γ + cell response and IFN-γ release concordance after in vitro SARS-CoV-2 stimulation시험관 내 SARS-CoV-2 자극 후 IFN-γ + 세포 반응 및 IFN-γ 방출 일치Article Published on 2021-12-012022-09-11 Journal: European Journal of Clinical Investigation [Category] SARS, 치료법, [키워드] Analysis anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody case-control study CD4 T-cell CD8 CD8 T-cell Cell cellular Cellular immune response cellular response Concordance convalescent COVID-19 cross-sectional determine ELISA exposed healthcare workers. flow cytometry greater HCW HCWs healthcare healthcare worker Healthcare workers IFN-γ immune in vitro increased risk individual Infection less magnitude proportion protective immunity quantification SARS-CoV-2 SARS-CoV-2-infected patients Stimulation susceptibility Symptoms T cell T cells T-cell Response uninfected Viral protein Viral proteins [DOI] 10.1111/eci.13636 PMC 바로가기 [Article Type] Article
Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern예측된 에피토프 풍부는 우려의 SARS-CoV-2 변이체에 대한 백신 유도 세포독성 보호를 지원합니다Immunology Published on 2021-11-252022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, [키워드] abundance affected Against allele alleles analyzed cellular Cellular immune response concern Critical cytotoxic Efficacy elicited Epidemic epitope Epitopes escape escape mutant escape mutation facilitate HLA HLA class I HLA class I alleles immune protection Mutation new virus protection SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants T cell epitope These data vaccination Vaccine vaccine efficacy variant [DOI] 10.3389/fimmu.2021.732693 PMC 바로가기 [Article Type] Immunology
SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patientsSARS-CoV-2 재조합 단백질은 COVID-19 회복기 환자의 샘플에서 뚜렷한 세포 및 체액 면역 반응 프로필을 자극합니다Original Article Published on 2021-11-232022-09-10 Journal: Clinics [Category] MERS, SARS, 진단, 치료기술, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Antigen antigens blood sample Blood samples CD3+ cellular Cellular immune response cellular immune responses cellular immunity chemiluminescence Contact contact with convalescent convalescent individual convalescent individuals coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 convalescent patient Determination domain Donor ELISA ELISAs examined groups humoral humoral immune response Humoral response IFN-γ IgG antibodies IgG antibody Immune profile immune response immune responses Immunity individual individuals investigated Lymphocytes membrane nucleocapsid overlapping Patient peptide peptide pool peptide pools peptides pool profile Proteins RBD Receptor-binding domain Recombinant protein recombinant proteins regions respiratory S1/S2 SARS-CoV-2 SARS-CoV-2 peptide SARS-CoV-2 peptides SARS-CoV-2 protein SARS-CoV-2 proteins SARS-CoV-2 spike sequence serum serum IgG antibodies serum IgG antibody severe acute respiratory syndrome Coronavirus shown stimulate Stimulation T cell T cells T lymphocyte T lymphocytes volunteers [DOI] 10.6061/clinics/2021/e3548 PMC 바로가기 [Article Type] Original Article
Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy PopulationArticle Published on 2021-11-232022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] Administered adverse event Antibody Response BNT162b2 mRNA boost booster Cellular immune response comparable conducted CoronaVac country Coverage COVID-19 COVID-19 pandemic Delta dosage dose effective Effects examined healthy IgG immunogenicity inactivated inactivated SARS-CoV-2 Intradermal intramuscular Intramuscular injection introduced less local reaction management mRNA vaccine neutralising observé of BNT162b2 participant Phase I Population provide provided randomised receiving recruited reduce regimen remained Safety SARS-CoV-2 serum significantly systemic reaction systemic side effects T cell response the vaccine Trial vaccination Vaccine vaccine immunogenicity Volunteer [DOI] 10.3390/vaccines9121375 PMC 바로가기 [Article Type] Article
Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosisResearch Article Published on 2021-11-222022-10-30 Journal: Neurological Research and Practice [Category] COVID-19, [키워드] age all subject Antibody Response B-cell depleted patients B-cell-depleted patients Cellular immune response cohorts Comirnaty® control group COVID-19 ELISpot assay evidence of healthy volunteers humoral IgG individual Lack of antibody response mRNA vaccination mRNA vaccine multiple sclerosis not differ Ocrelizumab Patient receiving reduced Registered Result SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination SARS-CoV2 vaccination semi-quantitative significantly T-cell mediated response vaccination were used while [DOI] 10.1186/s42466-021-00158-5 PMC 바로가기 [Article Type] Research Article
Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scaleSARS-CoV-2의 무증상 보균자의 감염은 인구 규모의 강력한 면역 달성을 방해할 수 있습니다Animal Published on 2021-11-172022-09-12 Journal: The Journal of General Virology [Category] MERS, SARS, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Analysis anti-RBD anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibodies Asymptomatic Asymptomatic carrier carried cell immunity Cellular immune response cellular immunity circulating Contact contact with coronavirus FIVE followed by generate herd immunity Humoral immunity IgG Immunity immunogenic infected with SARS-CoV-2 Infection interfere municipality pandemic Prevent ranged reduction in robust SARS-CoV-2 Seroconversion seroconversion rates severe acute respiratory syndrome Coronavirus Spread state virus Volunteer volunteers [DOI] 10.1099/jgv.0.001684 PMC 바로가기 [Article Type] Animal
Optimizing a Protocol to Assess Immune Responses after SARS-CoV-2 Vaccination in Kidney-Transplanted Patients: In Vivo DTH Cutaneous Test as the Initial Screening MethodCommunication Published on 2021-11-122022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] anti-Spike IgG can be used Cellular immune response classical complement control patients correlation COVID19 Cutaneous delayed-type hypersensitivity dose DTH evaluated hypersensitivity IgG immunized Immunocompromised patient Immunosuppression in vitro in vivo interferon gamma kidney transplant mRNA-based natural infection Patient patients Pfizer–BioNTech positive recipient response SARS-CoV-2 Screening second dose shown Skin test T-cell T-cell functionality T-cell Response Test the spike protein the vaccine vaccinated individuals vaccination Vaccine was determined [DOI] 10.3390/vaccines9111315 PMC 바로가기 [Article Type] Communication
Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvantArticle Published on 2021-11-082022-10-29 Journal: Scientific Reports [Category] COVID-19, MERS, SARS, [키워드] addition adjuvants Antigen antigen-specific antibody B.1.1.7 B.1.351 variant binding Body weight loss Cellular immune response convalescent plasma COVID-19 pandemic evaluated humoral Infectious diseases mice Neutralizing Neutralizing activity platform protein subunit vaccine Protein vaccines reducing robust SARS-CoV-2 SARS-CoV-2 vaccine single vaccination SLA sulfated the spike protein Vaccine Vaccines viral infection Viral load viral spike [DOI] 10.1038/s41598-021-01363-7 PMC 바로가기 [Article Type] Article
Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19Brief Communication Published on 2021-11-042022-10-30 Journal: NPJ Vaccines [Category] COVID-19, [키워드] adhere antibody BNT162b2 boost Cellular immune response chose clinical trial COVID-19 vaccination eight Heterologous heterologous prime-boost immunization humoral immune response Italian National public health receiving single dose small sample size Strong Support T-cell Response Vaccine vaccine candidate vaccine platform Vaccines Volunteer [DOI] 10.1038/s41541-021-00394-5 PMC 바로가기 [Article Type] Brief Communication
A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patientsRandomized Controlled Trial Published on 2021-11-012022-10-05 Journal: Phytotherapy research : PTR [Category] SARS, 임상, [키워드] accelerate administration Cellular immune response changes in Clinical outcome Clinical sign clinical trial COVID-19 COVID-19 patient COVID-19 patients Curcumin cytokine Cytokine storm effective evaluate the effect excessive immune response FOXP3 GATA3 Gene Expression IFN-γ IL-17 IL-4 Immunity Inflammation Inflammatory diseases inflammatory immune responses inflammatory phase Inflammatory responses investigated modulating per day Placebo placebo group placebo-controlled placebo-controlled study Randomized randomized clinical trial RORC Serum level severe complications significantly Signs and symptoms subtype suggested Symptoms TBX21 TGF-β triple-blind two group was done were measured [DOI] 10.1002/ptr.7294 PMC 바로가기 [Article Type] Randomized Controlled Trial